オンコロジー向けバイオシミラーの世界市場レポート 2024年

オンコロジー向けバイオシミラーの市場規模は、今後数年間で急激に成長すると予想されます。 2028年には16.8%の年間複合成長率（CAGR）で164億8,000万米ドルに成長すると予想されます。予測期間で予想される成長は、オンコロジー向けバイオシミラーポートフォリオの拡大、患者中心のケアモデルへの移行、医療費抑制の取り組み、標的療法の出現、この分野のパイプラインの継続的な成長など、いくつかの要因によって推進されます。この期間中に予想される主要動向には、バイオベッター（既存の生物学的医薬品の強化版）の開発、オンコロジー向けバイオシミラーの組み合わせ、支持療法のためのバイオシミラーの採用、この分野の進歩をサポートするための現実世界の証拠の利用が含まれます。

がん治療に利用される生物製剤の特許の期限切れにより、新しいオンコロジー向けバイオシミラーの開発が促進されています。生物由来の生物製剤には特許存続期間が限られており、低コストで同等の有効性を提供する、類似ではあるが同一ではない生物製剤の代替品であるバイオシミラーが登場する機会が生まれています。腫瘍生物学的製剤に関する20件近くの特許が2023年までに期限切れとなる予定であり、新しいオンコロジー向けバイオシミラーの作成が促されています。この特許失効率の上昇により、これらのバイオシミラーの需要が高まり、オンコロジー向けバイオシミラー市場の成長が促進されると予想されます。

がんとの闘いを目的とした政府の取り組みにより、オンコロジー向けバイオシミラー市場の成長が促進されようとしています。これらのイニシアチブは、特定の問題に対処したり特定の目的を達成したりするために、さまざまなレベルで政府機関によって導入された行動や政策を指します。がんの発生率を減らす取り組みにより、オンコロジー向けバイオシミラーの開発と採用に役立つ環境が生まれます。例えば、2022年にバイデン大統領はCancer Moonshotの復活を発表し、25年以内にがんによる死亡率を半減し、がん患者とがん生存者の生活を向上させるという新たな目標を設定しました。この取り組みは、連邦政府のリソースを結集してがん研究を加速し、改善された予防方法を促進します。したがって、がんと闘う政府主導の取り組みがオンコロジー向けバイオシミラー市場を刺激しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のオンコロジー向けバイオシミラー市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のオンコロジー向けバイオシミラー市場規模実績と成長、2018～2023年
• 世界のオンコロジー向けバイオシミラー市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のオンコロジー向けバイオシミラー市場、医薬品のタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• モノクローナル抗体
• 免疫調節剤
• 造血剤
• 顆粒球コロニー刺激因子（G-CSF）
• 世界のオンコロジー向けバイオシミラー市場、がんのタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 乳がん
• 結腸直腸がん
• 血液がん
• 好中球減少症がん
• 非小細胞肺がん
• その他
• 世界のオンコロジー向けバイオシミラー市場、流通タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域と国の分析

• 世界のオンコロジー向けバイオシミラー市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のオンコロジー向けバイオシミラー市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オンコロジー向けバイオシミラー市場の競合情勢
• オンコロジー向けバイオシミラー市場の企業プロファイル
  • Biocon Biologics Limited
  • Celltrion Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • STADA Arzneimittel AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Oncology biosimilars are medications designed to closely resemble biologic cancer treatments, providing comparable physiological effects. A common side effect of cancer therapy is decreased white blood cell counts, which can elevate the risk of infections.

Within oncology biosimilars, key drug types include monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators primarily target pathways involved in treating multiple myeloma and several other cancers. These treatments are utilized for various cancer types such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer. They are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2023 to $8.85 billion in 2024 at a compound annual growth rate (CAGR) of 28.3%. The growth observed in the historical period can be attributed to several factors, including an increased prevalence of cancer cases, patent expirations of biologic cancer drugs, governmental support for biosimilars, heightened investments in the development and manufacturing of biosimilar medications, and the widened global accessibility of biosimilar treatments.

The oncology biosimilars market size is expected to see exponentially grown in the next few years. It will grow to $16.48 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. Anticipated growth in the forecast period is driven by several factors, including the expansion of oncology biosimilar portfolios, a shift towards patient-centric care models, efforts to contain healthcare costs, the emergence of targeted therapies, and the continual growth of pipelines in this field. Major trends expected during this period encompass the development of biobetters (enhanced versions of existing biologic drugs), combinations of oncology biosimilars, the introduction of biosimilars for supportive care, and the utilization of real-world evidence to support advancements in this domain.

The expiration of patents on biologics utilized in cancer treatment is spurring the development of new oncology biosimilars. Biologics, derived from living organisms, have a limited patent lifespan, creating opportunities for the emergence of biosimilars similar but not identical alternatives to biologics that offer comparable effectiveness at reduced costs. Nearly 20 patents for oncology biologics are set to expire by 2023, prompting the production of new oncology biosimilars. This increased patent expiration rate is anticipated to drive demand for these biosimilars, fueling growth in the oncology biosimilars market.

Government initiatives aimed at combating cancer are poised to propel growth in the oncology biosimilars market. These initiatives denote actions or policies introduced by government bodies at various levels to address specific issues or achieve particular objectives. Efforts to reduce cancer rates create an environment conducive to the development and adoption of oncology biosimilars. For instance, in 2022, President Biden announced the revitalization of the Cancer Moonshot, setting new goals to halve the cancer death rate within 25 years and enhance the lives of cancer patients and survivors. This initiative marshals federal resources to accelerate cancer research, fostering improved prevention methods. Hence, government-led endeavors to combat cancer stimulate the oncology biosimilars market.

Pharmaceutical firms are increasingly channeling investments into research and development (R&D) to produce new oncology biosimilars. These companies recognize the burgeoning potential in the expanding biosimilar market and are bolstering their R&D capabilities to facilitate the research and production of novel biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration, with Coherus acquiring the rights to toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus intends to bolster its immuno-oncology portfolio using revenues generated from its commercial biosimilar endeavors.

Major players in the oncology biosimilars sector are directing investments toward cancer drugs to combat the disease. Their investments serve as a critical link between top-tier cancer care and sustainable healthcare solutions. For example, in March 2023, Pfizer, in a merger with Seagen, invested $43 billion to combat cancer. This move enhances Pfizer's presence in the oncology field, contributing significantly to the fight against cancer, a primary global cause of mortality.

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Baxter International Inc., Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Shanghai Henlius Biotech, Viatris Inc., Catalent Inc., Patheon, Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

North America was the largest region in the global oncology biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF)
• 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Other Cancer Types
• 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Companies Mentioned: Biocon Biologics Limited; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Oncology Biosimilars Market Size and Growth

• 5.1. Global Oncology Biosimilars Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Oncology Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Oncology Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oncology Biosimilars Market Segmentation

• 6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibody
• Immunomodulators
• Hematopoietic Agents
• Granulocyte Colony-Stimulating Factor (G-CSF)
• 6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Neutropenia Cancer
• Non-Small Cell Lung Cancer
• Other Cancer Types
• 6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

7. Oncology Biosimilars Market Regional And Country Analysis

• 7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

• 8.1. Asia-Pacific Oncology Biosimilars Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oncology Biosimilars Market

• 9.1. China Oncology Biosimilars Market Overview
• 9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oncology Biosimilars Market

• 10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oncology Biosimilars Market

• 11.1. Japan Oncology Biosimilars Market Overview
• 11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oncology Biosimilars Market

• 12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oncology Biosimilars Market

• 13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oncology Biosimilars Market

• 14.1. South Korea Oncology Biosimilars Market Overview
• 14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oncology Biosimilars Market

• 15.1. Western Europe Oncology Biosimilars Market Overview
• 15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oncology Biosimilars Market

• 16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oncology Biosimilars Market

• 17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oncology Biosimilars Market

• 18.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oncology Biosimilars Market

• 19.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oncology Biosimilars Market

• 20.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oncology Biosimilars Market

• 21.1. Eastern Europe Oncology Biosimilars Market Overview
• 21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oncology Biosimilars Market

• 22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oncology Biosimilars Market

• 23.1. North America Oncology Biosimilars Market Overview
• 23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oncology Biosimilars Market

• 24.1. USA Oncology Biosimilars Market Overview
• 24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oncology Biosimilars Market

• 25.1. Canada Oncology Biosimilars Market Overview
• 25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oncology Biosimilars Market

• 26.1. South America Oncology Biosimilars Market Overview
• 26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oncology Biosimilars Market

• 27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oncology Biosimilars Market

• 28.1. Middle East Oncology Biosimilars Market Overview
• 28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oncology Biosimilars Market

• 29.1. Africa Oncology Biosimilars Market Overview
• 29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Oncology Biosimilars Market Competitive Landscape
• 30.2. Oncology Biosimilars Market Company Profiles
  • 30.2.1. Biocon Biologics Limited
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Celltrion Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Dr. Reddy's Laboratories Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Intas Pharmaceuticals Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. STADA Arzneimittel AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Oncology Biosimilars Market Competitive Benchmarking

32. Global Oncology Biosimilars Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

34. Oncology Biosimilars Market Future Outlook and Potential Analysis

• 34.1 Oncology Biosimilars Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Oncology Biosimilars Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Oncology Biosimilars Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer